A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy

For estrogen receptor (ER)-negative breast cancer patients, paclitaxel (P), doxorubicin (A) and cyclophosphamide (C) neoadjuvant chemotherapy (NAC) is the standard therapeutic regimen. Pathologic complete response (pCR) and residual disease (RD) are common surrogate measures of chemosensitivity. Aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yanhua, Cai, Hao, Chen, Wannan, Guan, Qingzhou, He, Jun, Guo, Zheng, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109260/
https://www.ncbi.nlm.nih.gov/pubmed/32269999
http://dx.doi.org/10.3389/fmolb.2020.00034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109260/
https://www.ncbi.nlm.nih.gov/pubmed/32269999
http://dx.doi.org/10.3389/fmolb.2020.00034

Ejemplares similares